Posted by Michael Wonder on 13 Oct 2022
Nevro announces FDA approval of HFX iQ spinal cord stimulation system to personalise the treatment of chronic pain
12 October 2022 - Next generation Senza HFX iQ is the first and only spinal cord stimulation system that uses artificial intelligence to optimise and maintain pain relief using each patient's response.
Nevro today announced that it has received approval from the US FDA for the Senza HFX iQ spinal cord stimulation system.
